BR100 Increased By (0.01%)
BR30 Increased By (0.53%)
KSE100 Increased By (0.28%)
KSE30 Increased By (0.29%)
AGHA 6.38 Increased By ▲ 0.06 (0.95%)
BECO 4.35 Increased By ▲ 0.08 (1.87%)
BML 62.55 Increased By ▲ 0.10 (0.16%)
BOP 31.39 Increased By ▲ 0.16 (0.51%)
CNERGY 11.73 Increased By ▲ 0.14 (1.21%)
CSIL 5.91 Increased By ▲ 0.19 (3.32%)
FCCL 61.71 Increased By ▲ 0.17 (0.28%)
FFL 14.79 Decreased By ▼ -0.23 (-1.53%)
FNEL 1.24 Increased By ▲ 0.01 (0.81%)
KEL 6.32 Increased By ▲ 0.06 (0.96%)
KOSM 5.90 Increased By ▲ 0.34 (6.12%)
LOTCHEM 24.69 Increased By ▲ 0.01 (0.04%)
MLCF 103.93 Decreased By ▼ -0.15 (-0.14%)
NBP 173.32 Decreased By ▼ -1.96 (-1.12%)
NCPL 51.83 Decreased By ▼ -0.94 (-1.78%)
NPL 54.03 Decreased By ▼ -0.09 (-0.17%)
OGDC 315.87 Increased By ▲ 2.48 (0.79%)
PACE 9.26 Increased By ▲ 0.06 (0.65%)
PAEL 35.58 Decreased By ▼ -0.22 (-0.61%)
PIBTL 13.66 Increased By ▲ 0.19 (1.41%)
PPL 226.07 Increased By ▲ 4.26 (1.92%)
PRL 80.28 Increased By ▲ 1.20 (1.52%)
PTC 46.64 Decreased By ▼ -0.21 (-0.45%)
SSGC 23.82 Decreased By ▼ -0.05 (-0.21%)
TBL 9.24 Decreased By ▼ -0.07 (-0.75%)
TELE 7.55 Increased By ▲ 0.16 (2.17%)
TPL 24.54 Decreased By ▼ -0.57 (-2.27%)
TPLP 12.99 Increased By ▲ 0.48 (3.84%)
TREET 25.98 Decreased By ▼ -0.27 (-1.03%)
TRG 53.33 Decreased By ▼ -0.11 (-0.21%)
اردو
Android App
Print Edition Dollar to PKR
Daily Petrol Prices IMF-World Bank meetings Intl Oil Prices Iran-US war Gold Rates Podcasts PSX Notices
Topic

Merck & Co Inc

Merck sees bigger 2021 sales hit after first quarter feels pandemic pain

Merck sees bigger 2021 sales hit after first quarter feels pandemic pain

Published 29 Apr, 2021 06:40pm
  • Shares fell nearly 2% to $75.70 before the opening bell as the health crisis also led to a roughly $600 million drop in first-quarter sales.
  • Sales of Merck's Gardasil, a vaccine to prevent cancers caused by the human papillomavirus virus, tumbled 16.4% to $917 million in the first quarter, hurt by lower demand in the United States and Europe.
Merck plans large outpatient trial of COVID-19 pill, stops study in hospitalized patients

Merck plans large outpatient trial of COVID-19 pill, stops study in hospitalized patients

Published 15 Apr, 2021 04:25pm
  • The company said it would study the drug molnupiravir in a Phase 3 trial among COVID-19 patients out of hospitals who have at least one risk factor for poor outcomes, such as advanced age, obesity or diabetes.
  • Merck also said it discontinued development of an experimental immune modulator, known as MK-7110, for treating COVID-19 after concluding that clinical trial and manufacturing preparations would take too long.
Gilead, Merck collaborate to develop long-acting HIV treatment

Gilead, Merck collaborate to develop long-acting HIV treatment

Updated 15 Mar, 2021 09:24pm
  • As part of the non-exclusive agreement, the companies hope to develop a therapy that allows for less frequent dosing, compared to the current once-daily treatments available to HIV patients.
  • "The market will infer that GSK and ViiV are left out in the cold here, supporting our long-standing concerns over the longer term outlook for GSK's HIV franchise."
Biden calls on states to prioritize vaccinations for teachers

Biden calls on states to prioritize vaccinations for teachers

Published 03 Mar, 2021 10:23am
  • He said the department would also act as a clearing house for best practices and lessons learned during the pandemic, while updating a handbook of strategies for meeting students' needs and addressing the loss of instructional time.
Merck to help make Johnson & Johnson's COVID-19 vaccine

Merck to help make Johnson & Johnson's COVID-19 vaccine

Published 02 Mar, 2021 08:34pm
  • After scrapping development of its own COVID-19 vaccine candidates in January, Merck last month said it was working on a deal to open up its manufacturing capacity to other vaccine makers.
  • J&J is shipping about four million doses of its vaccine in the United States this week, but the next shipments hinge on when its new, larger manufacturing plant receives regulatory approvals.
Merck to buy drug developer Pandion Therapeutics for $1.85bn

Merck to buy drug developer Pandion Therapeutics for $1.85bn

Published 25 Feb, 2021 06:59pm
  • The $60-per-share deal represents about 134% premium to Pandion's closing price on Wednesday.
  • Pandion's lead drug candidate, PT101, last month met its main goals of safety and tolerability in an early-stage trial in patients with autoimmune diseases.
Loading...